BIONIK Laboratories to Participate at the American Physical Therapy Association Conference

Company to Showcase its InMotion® Arm/Hand at the Country’s Largest Physical Therapy Conference from February 2-5, 2022

BOSTON–(BUSINESS WIRE)–BIONIK Laboratories Corp. (OTCQB: BNKL) (“BIONIK” or the “Company”), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced its participation in the American Physical Therapy Association (APTA) Conference in San Antonio, Texas from February 2–5, 2022.

At the APTA conference, BIONIK will highlight InMotion®’s ability to deliver intensive therapy to help patients regain motor function following a stroke and other neurological conditions or injuries. While conventional therapy will allow physical therapists to complete about 30-60 movements per session, BIONIK’s InMotion Arm/Hand device will allow clinicians to track up to 1,000 movements per session. InMotion® therapy guides the patient through specific tasks, aiming to improve motor control of the arm and hand by increasing strength, range of motion and coordination, and assisting with the provision of efficient, effective, and intensive sensorimotor therapy. In addition to the robotic device, the Company will also showcase its cloud-based data analytics solution, InMotion Connect™, which securely collects patient data from the InMotion® robots. The easy-to-use platform features a customized dashboard to review patients’ insights at the clinician’s fingertips.

“APTA hosts the country’s largest physical therapy conference, attended by thousands of physical therapists and potential buyers. Our presence at APTA gives us the opportunity to showcase how our devices can make an immediate impact to patients and facilities. At this conference we’ll be demonstrating our InMotion® Arm/Hand to potential buyers and industry professionals in person,” said Richard Russo, Jr., Chief Financial Officer and Interim Chief Executive Office of BIONIK. “We look forward to sharing the benefits of our InMotion® device as well as the ongoing training, education and support that we provide for patient results.”

InMotion® Robots were developed according to the principles of motor learning and neuro-plasticity, using AI and measuring the position, the speed and the acceleration of the upper limb 200 times a second. The results center around the Company’s emphasis on technology adoption with its partner facilities to ensure successful utilization and patient results. The InMotion® robotic therapy systems are used regularly in more than 15 countries to help stroke survivors and those with other neurological conditions regain movement by training shoulder protraction/retraction, flexion/extension, abduction/adduction, internal/external rotation and elbow flexion/extension. To learn more, please visit www.bioniklabs.com.

APTA is a professional organization that represents 100,000 physical therapists, physical therapist assistants, and students of physical therapy. The association’s focus is on building a community that advances the profession of physical therapy to improve the health of society, while providing networking opportunities with thousands of conference attendees.

About BIONIK Laboratories Corp.

BIONIK Laboratories is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and three products in varying stages of development.

For more information, please visit www.BIONIKlabs.com and connect with us on Twitter, LinkedIn, and Facebook.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other robotic rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, pipeline of potential sales, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the market and projected market for our existing and planned products and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the inability to meet listing standards to uplist to a national stock exchange, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the impact on the Company’s business as a result of the Covid-19 pandemic, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company’s raw materials, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company does not undertake to update these forward-looking statements.

Contacts

Media:
Ashley Willis

FischTank PR

Ashley@fischtankpr.com

Investor Relations:
Stephanie Prince

PCG Advisory

sprince@pcgadvisory.com
646.863.6341